128 related articles for article (PubMed ID: 35421669)
1. Activation of YAP1 by STK25 contributes to the progression of hepatocellular carcinoma.
Jiang J; Zheng Y; Chen F; Dong L; Guo X
Tissue Cell; 2022 Jun; 76():101797. PubMed ID: 35421669
[TBL] [Abstract][Full Text] [Related]
2. Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways.
Kurhe Y; Caputo M; Cansby E; Xia Y; Kumari S; Anand SK; Howell BW; Marschall HU; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2022; 13(2):405-423. PubMed ID: 34624527
[TBL] [Abstract][Full Text] [Related]
3. Deubiquitinating enzyme USP46 suppresses the progression of hepatocellular carcinoma by stabilizing MST1.
Qiu Y; Huang D; Sheng Y; Huang J; Li N; Zhang S; Hong Z; Yin X; Yan J
Exp Cell Res; 2021 Aug; 405(1):112646. PubMed ID: 34029571
[TBL] [Abstract][Full Text] [Related]
4. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene.
Zhou D; Conrad C; Xia F; Park JS; Payer B; Yin Y; Lauwers GY; Thasler W; Lee JT; Avruch J; Bardeesy N
Cancer Cell; 2009 Nov; 16(5):425-38. PubMed ID: 19878874
[TBL] [Abstract][Full Text] [Related]
5. LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis.
Guo C; Wang X; Liang L
Int J Clin Exp Pathol; 2015; 8(2):1690-7. PubMed ID: 25973055
[TBL] [Abstract][Full Text] [Related]
6. miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression.
Chen M; Wu L; Tu J; Zhao Z; Fan X; Mao J; Weng Q; Wu X; Huang L; Xu M; Ji J
EBioMedicine; 2018 Sep; 35():142-154. PubMed ID: 30111512
[TBL] [Abstract][Full Text] [Related]
7. Dihydroartemisinin inhibited interleukin-18 expression by decreasing YAP1 in hepatocellular carcinoma cells.
Gong Y; Peng Q; Gao Y; Yang J; Lu J; Zhang Y; Yang Y; Liang H; Yue Y; Shi X
Acta Histochem; 2023 May; 125(4):152040. PubMed ID: 37119608
[TBL] [Abstract][Full Text] [Related]
8. STK25 enhances hepatocellular carcinoma progression through the STRN/AMPK/ACC1 pathway.
Zhang Y; Xu J; Qiu Z; Guan Y; Zhang X; Zhang X; Chai D; Chen C; Hu Q; Wang W
Cancer Cell Int; 2022 Jan; 22(1):4. PubMed ID: 34986838
[TBL] [Abstract][Full Text] [Related]
9. The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas.
Lee K; Lee KB; Jung HY; Yi NJ; Lee KW; Suh KS; Jang JJ
BMC Cancer; 2017 Jun; 17(1):441. PubMed ID: 28645247
[TBL] [Abstract][Full Text] [Related]
10. Activation of YAP1 by N6-Methyladenosine-Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma.
Chen Y; Ling Z; Cai X; Xu Y; Lv Z; Man D; Ge J; Yu C; Zhang D; Zhang Y; Xie H; Zhou L; Wu J; Zheng S
Cancer Res; 2022 Feb; 82(4):599-614. PubMed ID: 34916222
[TBL] [Abstract][Full Text] [Related]
11. SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET.
He Q; Lin Z; Wang Z; Huang W; Tian D; Liu M; Xia L
Oncogene; 2020 Dec; 39(50):7279-7295. PubMed ID: 33046796
[TBL] [Abstract][Full Text] [Related]
12. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
[TBL] [Abstract][Full Text] [Related]
13. Early growth response 3 inhibits growth of hepatocellular carcinoma cells via upregulation of Fas ligand.
Zhang S; Xia C; Xu C; Liu J; Zhu H; Yang Y; Xu F; Zhao J; Chang Y; Zhao Q
Int J Oncol; 2017 Mar; 50(3):805-814. PubMed ID: 28098878
[TBL] [Abstract][Full Text] [Related]
14. LINC00707 promotes hepatocellular carcinoma progression through activating ERK/JNK/AKT pathway signaling pathway.
Wang J; Luo Z; Yao T; Li W; Pu J
J Cell Physiol; 2019 May; 234(5):6908-6916. PubMed ID: 30317590
[TBL] [Abstract][Full Text] [Related]
15. Transcription factor specificity protein 1-mediated Serine/threonine kinase 39 upregulation promotes the proliferation, migration, invasion and epithelial-mesenchymal transition of hepatocellular carcinoma cells by activating the transforming growth factor-β1 /Smad2/3 pathway.
Wang J; Fan Z; Li J; Yang J; Liu X; Cheng J
Bioengineered; 2021 Dec; 12(1):3566-3577. PubMed ID: 34281492
[TBL] [Abstract][Full Text] [Related]
16. PIGU promotes hepatocellular carcinoma progression through activating NF-κB pathway and increasing immune escape.
Wei X; Yang W; Zhang F; Cheng F; Rao J; Lu L
Life Sci; 2020 Nov; 260():118476. PubMed ID: 32971102
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) is a potential diagnostic and prognostic biomarker and therapeutic target for hepatocellular carcinoma.
Guo C; Zhou S; Yi W; Yang P; Li O; Liu J; Peng C
Exp Mol Pathol; 2021 Jun; 120():104638. PubMed ID: 33878313
[TBL] [Abstract][Full Text] [Related]
18. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
19. Targeting Yes1 Associated Transcriptional Regulator Inhibits Hepatocellular Carcinoma Progression and Improves Sensitivity to Sorafenib: An in vitro and in vivo Study.
Guo L; Zheng J; Luo J; Zhang Z; Shao G
Onco Targets Ther; 2020; 13():11071-11087. PubMed ID: 33149619
[TBL] [Abstract][Full Text] [Related]
20. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
